Bright Minds Biosciences DRUG 深 沪
等待开盘 05-18 09:30:00 美东时间
77.47
-0.170
-0.22%
华盛通- 最 高81.62
- 今 开77.27
- 成交量 26.99万股
- 最 低 73.78
- 昨 收 77.64
- 总市值 7.58亿
- 52周最高 123.75
- 市盈率 静 --
- 换手率 2.76%
- 52周最低 23.175
- 委 比 -33.33%
- 总股本 978.72万
- 历史最高 123.75
- 量 比 1.44
- 振 幅 10.10%
- 历史最低 0.93
- 每 手 1
- 风险率 22.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145
Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.
04-13 20:21
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
03-30 17:57
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
03-28 01:28
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raises the price target from $115 to $145.
03-05 00:04
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences, Inc., a biotech company focusing on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders, will present at three upcoming conferences: TD Cowen Health Care Conference (March 4, 9:10am ET, webcast available), Leerink Partners Global Healthcare Conference (March 9, no webcast), and Jefferies Biotech on the Beach (March 10, 1x1 meetings).
02-25 21:30
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
BTIG Maintains Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
02-17 19:00
